Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Eli Lilly (LLY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and ...

With just one subscription to Beyond the Wall Investing , you can save thousands of dollars a year on equity research reports from banks. You'll keep your finger on the pulse and have access to the latest and highest-quality analysis of this type of information.My very first article on Pfizer Inc. (NYSE: PFE ) stock came out in mid-February 2024 with a "Buy" rating as I was arguing that PFE's depressed valuation and strong product pipeline made it "the ultimate buyingHe leads the investing group Beyond the ...

At ELAM1, we empower financial professionals and investors with the scientific and clinical expertise required to navigate the complexities of the healthcare sector. By bridging the gap between cutting-edge science and financial strategy, we help our clients uncover hidden value, assess risks with greater accuracy, and make more informed investment decisions in life sciences. Feel free to reach us or to visit our website for more informations about us and our services.Analyst’s Disclosure: I/we have a benef ...

Most people like to buy products when prices are cheaper. That's why you'll probably see lots of car dealers, furniture stores, and retailers advertising special sales during the Memorial Day weekend.However, many investors are leery of buying a stock that has fallen sharply. Why? It's often because they're worried about getting caught in a value trap.But sometimes beaten-down stocks offer great bargains to forward-thinking investors. Pfizer (PFE 1.28%) is a great example, with its shares down around 57% be ...

Pfizer TodayPFEPfizer$23.34 +0.31 (+1.32%) 52-Week Range$20.92▼$31.54Dividend Yield7.37%P/E Ratio16.54Price Target$29.17Add to WatchlistA dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. NYSE: PFE certainly catches the eye of income-seeking investors. Such a substantial return often signals a mature, stable company generously rewarding its shareholders. However, a closer look reveals a complex picture for the New York-based drugmaker. Get Pfizer alerts:Does this impres ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with placebo plus ADT XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with meta ...

Pfizer Inc. ( NYSE: PFE ) is one of the most well-known companies in the pharma sector. This analysis will show that PFE is currently an attractive value play due to its low relativeMy main area of interest is algorithmic trading and trading strategies. However, I am also very interested in macroeconomic topics, especially since I lived and studied in Shanghai for half a year. That is why I plan to write about those topics with a focus on China. I am one semester away from finishing my bachelor's degree in ...

SEONGNAM, South Korea, May 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it the Supreme Court of Korea has ruled in its favor in a patent infringement lawsuit filed by large global pharmaceutical giant Pfizer over its 13-valent pneumococcal conjugate vaccine (PCV13). In 2020, Pfizer claimed that SK bioscience's export of PCV13 individual conjugate bulk substances and research-use finis ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.It did not take long for Pfizer Inc. (NYSE: PFE ) to change its mind on its oncology pipe ...

Pfizer (PFE) announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio.3SBio is already developing SSGJ-707 in China for non-small cell lung cancer (“NSCLC”), metastatic colorectal cancer, and gynecological tumors, with the first phase III study expected to begin this year.Unlike the currently available marketed products, which target only the PD-1 protein, SSGJ-707 targets two proteins ...